Una combinación de entrenamiento aeróbico y de fuerza podría funcionar mejor que solo uno de los dos tipos de ejercicio por sí mismo para ayudar a los diabéticos a controlar el azúcar en sangre, halla una revisión reciente.
Los adultos jóvenes que abandonan sus hábitos malos de salud pueden reducir su riesgo de enfermedad cardiaca a medida que envejecen, sugiere una investigación reciente.
Los niveles bajos de vitamina D podrían ser una causa de hipertensión, según un estudio reciente.
Unos investigadores afirman haber desarrollado un análisis de sangre que puede detectar el rechazo de un trasplante de corazón semanas o meses antes de lo que ha sido posible anteriormente
Las personas que viven en vecindarios donde caminar resulta fácil son menos propensas a tener sobrepeso o ser obesas, y también tienen unas tasas más bajas de diabetes.
The SynCardia total artificial heart with SynHall valves has received CE mark approval. The CE mark gives SynCardia systems control over the last critical component for SynCardia heart manufacturing.
InspireMD has announced that it is attending EuroPCR 2014, the leading cardiovascular event in Europe. The conference is taking place in Paris, France from 20-23 May 2014.
Elixir Medical Corporation has announced that it has received CE mark approval for its DESolve 100 novolimus-eluting bioresorbable coronary scaffold system.
St Jude Medical has announced the first patient implants in the US IDE PORTICO trial. The trial is evaluating the Portico transcatheter aortic valve system, the first aortic heart valve that is repositionable until fully deployed. The trial will enrol patients who are considered to have a high or an extreme surgical risk (meaning they would not be considered) for open-heart surgery.
InspireMD has announced new results from the iMOS (International MGuard Observational Study) Prime registry demonstrating that use of the MGuard Prime in cases of acute ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention resulted in complete ST-resolution in approximately 75% of cases, and a 2.2% rate of major adverse cardiac events (MACE) at 30 days, including zero cases of mortality.
Biosensors has announced that the US Food and Drug Administration (FDA) recently granted conditional investigational device exemption (IDE) approval for a US-based clinical trial of the BioFreedom polymer-free drug-coated stent system.
Eurocor has launched its Apertus aspiration catheter. The catheter is specifically designed for enhanced fast and accurate thrombus aspiration. The new device is being marketed in over 50 countries worldwide.
CardiAQ Valve Technologies (CardiAQ) has announced that the European Patent Office Legal Division issued a temporary stay of further proceedings in Neovasc’s pending European patent application covering transcatheter mitral valve implantation technology. This action comes as the initial result of the lawsuit filed late June 2014 in Germany by CardiAQ against Neovasc.
According to a report in The Journal of Thoracic and Cardiovascular Surgery, totally endoscopic aortic valve replacement (TEAVR) is technically feasible. Lead author of the report Marco Vola (Cardiovascular Surgery Unit, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France) talks to Cardiovascular News about TEAVR and its potential role in the management of patients with aortic stenosis.
The Women Committee of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) has been set up to attain gender equality in interventional cardiology at the professional and patient level. The chair of the committee, Julinda Mehilli (Munich University Clinic, Ludwig-Maximilian University, Munich, Germany), speaks to Cardiovascular News about why the comparative lack of women in interventional cardiology means that the specialty is “losing more than 50% of the talent pool”.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos